Current Controlled Trials in Cardiovascular Medicine (Oct 2004)

Elevated levels of matrix metalloprotein-3 in patients with coronary aneurysm: A case control study

  • Duman Can,
  • Sekuri Cevad,
  • Aliyev Emil,
  • Ercan Ertugrul,
  • Tengiz Istemihan,
  • Altuglu Imre

DOI
https://doi.org/10.1186/1468-6708-5-10
Journal volume & issue
Vol. 5, no. 1
p. 10

Abstract

Read online

Abstract Background Matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of arterial aneurysms through increased proteolysis of extracellular matrix proteins. Increased proteolysis due to elevated matrix degrading enzyme activity in the arterial wall may act as a susceptibility factor for the development of coronary aneurysms. The aim of this study was to investigate the association between MMPs and presence of coronary aneurysms. Methods Thirty patients with aneurysmal coronary artery disease and stable angina were enrolled into study (Group 1). Fourteen coronary artery disease patients with stable angina were selected as control group (Group 2). MMP-1, MMP-3 and C-reactive protein (CRP) were measured in peripheral venous blood and matched between the groups. Results Serum MMP-3 level was higher in patients with aneurismal coronary artery disease compared to the control group (20.23 ± 14.68 vs 11.45 ± 6.55 ng/ml, p = 0.039). Serum MMP-1 (13.63 ± 7.73 vs 12.15 ± 6.27 ng/ml, p = 0.52) and CRP levels (4.78 ± 1.47 vs 4.05 ± 1.53 mg/l, p = 0.13) were not significantly different between the groups. Conclusion MMPs can cause arterial wall destruction. MMP-3 may play role in the pathogenesis of coronary aneurysm development through increased proteolysis of extracellular matrix proteins.